Literature DB >> 23814599

A case of isolated pulmonary mucormycosis in an immunocompetent host.

Jung Su Lee1, Ho Cheol Kim, Sang Woo Park, Hoon Sub So, Chang Yun Woo, Jong Han Choi, Sang Hyung Kim, Se Jin Kim, Yeon-Mok Oh.   

Abstract

Mucormycosis is a rare fungal disease that holds a fatal opportunistic fungal infection in diabetes mellitus, hematological malignancy, and immunocompromised host. Isolated pulmonary mucormycosis is extremely rare. Optimal therapy is a combined medical-surgical approach and a management of the patient's underlying disease. Herein, we report a case-study of isolated pulmonary mucormycosis which was being presented as multiple lung nodules in a patient with no underlying risk factors. Considering that the patient had poor pulmonary functions, we treated him with only antifungal agent rather than a combined medical-surgical approach. After treatment with antifungal agent for six months, the nodules of pulmonary mucormycosis were improved with the prominent reductions of size on the computed tomography.

Entities:  

Keywords:  Immunocompetence; Lung; Mucormycosis; Posaconazole

Year:  2013        PMID: 23814599      PMCID: PMC3695309          DOI: 10.4046/trd.2013.74.6.269

Source DB:  PubMed          Journal:  Tuberc Respir Dis (Seoul)        ISSN: 1738-3536


  6 in total

Review 1.  Pulmonary mucormycosis.

Authors:  Georgios Hamilos; George Samonis; Dimitrios P Kontoyiannis
Journal:  Semin Respir Crit Care Med       Date:  2011-12-13       Impact factor: 3.119

Review 2.  Pathogenesis of mucormycosis.

Authors:  Ashraf S Ibrahim; Brad Spellberg; Thomas J Walsh; Dimitrios P Kontoyiannis
Journal:  Clin Infect Dis       Date:  2012-02       Impact factor: 9.079

Review 3.  Epidemiology and clinical manifestations of mucormycosis.

Authors:  George Petrikkos; Anna Skiada; Olivier Lortholary; Emmanuel Roilides; Thomas J Walsh; Dimitrios P Kontoyiannis
Journal:  Clin Infect Dis       Date:  2012-02       Impact factor: 9.079

4.  Risk factors for mortality in patients with mucormycosis.

Authors:  Brad Spellberg; Dimitrios P Kontoyiannis; David Fredricks; Michele I Morris; John R Perfect; Peter V Chin-Hong; Ashraf S Ibrahim; Eric P Brass
Journal:  Med Mycol       Date:  2012-03-21       Impact factor: 4.076

Review 5.  Mucormycosis in hematologic patients.

Authors:  Livio Pagano; Massimo Offidani; Luana Fianchi; Annamaria Nosari; Anna Candoni; Marco Picardi; Laura Corvatta; Domenico D'Antonio; Corrado Girmenia; Pietro Martino; Albano Del Favero
Journal:  Haematologica       Date:  2004-02       Impact factor: 9.941

6.  Isolated pulmonary mucormycosis in an apparently normal host: a case report.

Authors:  A Butala; B Shah; Y T Cho; M F Schmidt
Journal:  J Natl Med Assoc       Date:  1995-08       Impact factor: 1.798

  6 in total
  4 in total

Review 1.  Pulmonary Mucormycosis Over 130 Years: A Case Report and Literature Review.

Authors:  Hasan S Yamin; Amro Y Alastal; Izzedin Bakri
Journal:  Turk Thorac J       Date:  2017-01-01

2.  Characteristics of pulmonary mucormycosis and predictive risk factors for the outcome.

Authors:  Jun Feng; Xuefeng Sun
Journal:  Infection       Date:  2018-05-10       Impact factor: 3.553

3.  Clinical features of pulmonary mucormycosis in patients with different immune status.

Authors:  Min Peng; Hua Meng; Yinghao Sun; Yu Xiao; Hong Zhang; Ke Lv; Baiqiang Cai
Journal:  J Thorac Dis       Date:  2019-12       Impact factor: 2.895

4.  Rhizopus microsporus lung infection in an immunocompetent patient successfully treated with amphotericin B: A case report.

Authors:  Long Chen; Yuan Su; Xian-Zhi Xiong
Journal:  World J Clin Cases       Date:  2021-12-16       Impact factor: 1.337

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.